학술논문
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.
Document Type
Article
Author
Ivashchenko, Andrey A; Dmitriev, Kirill A; Vostokova, Natalia V; Azarova, Valeria N; Blinow, Andrew A; Egorova, Alina N; Gordeev, Ivan G; Ilin, Alexey P; Karapetian, Ruben N; Kravchenko, Dmitry V; Lomakin, Nikita V; Merkulova, Elena A; Papazova, Natalia A; Pavlikova, Elena P; Savchuk, Nikolay P; Simakina, Elena N; Sitdekov, Tagir A; Smolyarchuk, Elena A; Tikhomolova, Elena G; Yakubova, Elena V
Source
Subject
*PILOT projects
*DRUG approval
*COVID-19
*RANDOMIZED controlled trials
*DESCRIPTIVE statistics
*GOVERNMENT agencies
*ENZYME inhibitors
*PATIENT safety
*
*
*
*
*
*
*
Language
ISSN
1058-4838
Abstract
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248. [ABSTRACT FROM AUTHOR]